[
    [
        {
            "time": "2023-10-10",
            "original_text": "Healthcare Dividend Stocks Hedge Funds are Buying",
            "features": {
                "keywords": [
                    "Healthcare",
                    "Dividend",
                    "Hedge",
                    "Funds"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Healthcare Dividend Stocks Hedge Funds are Buying",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2023-10-10",
            "original_text": "Jim Cramer: The Fortunes Have Been Restored for Regeneron and Abbott",
            "features": {
                "keywords": [
                    "Jim Cramer",
                    "Regeneron",
                    "Abbott",
                    "Fortunes",
                    "Restored"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Jim Cramer: The Fortunes Have Been Restored for Regeneron and Abbott",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-10",
            "original_text": "Abbott Labs Is Poised to Break Out to New Highs",
            "features": {
                "keywords": [
                    "Abbott Labs",
                    "Poised",
                    "Break Out",
                    "New Highs"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Abbott Labs Is Poised to Break Out to New Highs",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]